Fig. 2: Spheroid destruction following ZHER2:2395–IR700 conjugate-based phototherapy.
From: Immunomodulatory activity of IR700-labelled affibody targeting HER2
A Dose-dependent decrease in SKOV-3 spheroid viability as assessed by the CellTiter-Glo® 3D luminescent cell viability assay 96 h post-treatment, following 6 h incubation with the ZHER2:2395–IR700 (0.1–1 µM) with or without blocking with 50-fold excess of unlabelled ZHER2:2395 or IR700 (1 µM) and irradiation with 16 J/cm2 NIR light dose. Data are presented as mean ± SEM (n = 3). Statistical significance in comparison to the control (untreated) group was determined using ANOVA with Dunnett post hoc test. ****p ≤ 0.0001. B Confocal MIP images illustrating live/dead staining assay of the SKOV-3 spheroids conducted 96 h post-phototherapy. Live—calcein AM fluorescence (live cells, green); Dead—signal from ethidium homodimer-1 bound to DNA (dead cells, red). Hoechst®33342 (blue) used as a counterstain of nuclei. C Changes in the morphology of SKOV-3 spheroids captured via Celigo® cytometer pre- and 1, 24, 96 h post-treatment.
